Efficacy and Safety of the Bruton's Tyrosine Kinase...

Multiple Sclerosis and Related Disorders 2020 / 01 Vol. 37

Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Patients with Relapsing Multiple Sclerosis Over 48 Weeks: A Randomized, Placebo-Controlled, Phase 2 Study

Montalban, Xavier, Arnold, Douglas L, Weber, Martin S, Staikov, Ivan, Piasecka-Stryczynska, Karolina, Martin, Emily C, Syed, Sana, Dangond, Fernando, Wolinsky, Jerry S
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
37
Journal:
Multiple Sclerosis and Related Disorders
DOI:
10.1016/J.MSARD.2019.11.078
Date:
January, 2020
File:
PDF, 106 KB
2020
Conversion to is in progress
Conversion to is failed